Abstract
SummaryElectrical cardioversion is usually performed when ventricular tachycardia and ventricular fibrillation occur following the release of the aortic cross‐clamp during cardiopulmonary bypass. However, electrical cardioversion has been associated with myocardial damage. Pharmacological cardioversion for ventricular dysrhythmia in cardiac surgery may be advantageous. We report four successful cases of pharmacological cardioversion using nifekalant, a pure potassium‐channel blocker, for ventricular tachycardia and ventricular fibrillation following the release of aortic cross‐clamp during cardiac surgery. We argue that pharmacological cardioversion by nifekalant has certain advantages over electrical cardioversion because it may suppress myocardial damage.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
